NYSE$MCK
McKesson Corp · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
McKesson reported third-quarter results with revenue growth and increased adjusted earnings per share.
McKesson reported a 6% increase in third-quarter revenues, reaching $62.6 billion. Adjusted earnings per diluted share rose by 21% to $4.60. The company recorded a pre-tax charge of $8.1 billion related to opioid litigation, resulting in a Loss per diluted share of $(39.03).
- Total revenues reached $62.6 billion, a 6% increase year-over-year.
- Loss per diluted share was $(39.03), impacted by an $8.1 billion pre-tax charge related to opioid litigation.
- Adjusted Earnings per diluted share increased by 21% to $4.60.
- The Board of Directors authorized an additional $2.0 billion share repurchase program.
Headline financials
Revenue & EPS history
McKesson · Revenue · Quarterly
$62.6B
Revenue by segment
McKesson · $3.83B total across 2 segments · Q3 2021
- Medical-Surgical Solutions$3.05B+42.6%79.7%
- Prescription Technology Solutions$777M+8.8%20.3%
Forward guidance
McKesson raised and narrowed fiscal 2021 Adjusted Earnings per diluted share guidance to $16.95 to $17.25 from the previous range of $16.00 to $16.50 to primarily reflect improved growth in the business and the contribution from McKesson’s successful distribution of COVID-19 vaccines and ancillary supplies.
Tailwinds
- Improved growth in the business.
- Contribution from McKesson’s successful distribution of COVID-19 vaccines and ancillary supplies.
- Expect Adjusted Earnings per diluted share of $16.95 to $17.25.
- COVID-19 vaccine distribution is expected to contribute $0.25 to $0.35.
- Kitting and distribution of ancillary supplies for COVID-19 vaccines is expected to contribute $0.20 to $0.30.
Headwinds
- Overall environment remains challenging due to the sustained impact of the COVID-19 pandemic.
- A full recovery of pharmaceutical prescription volumes and patient visits will not occur this fiscal year.
- Opioid-related claims of governmental entities resulted in a pre-tax charge of $8.1 billion.
- Long-lived asset impairment charge of $115 million primarily related to McKesson’s retail pharmacy businesses in the International segment.
- Higher tax rate and the lapping of the prior year contribution from the company's now separated investment in Change Healthcare LLC
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+1.2%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+1.1%
Avg return
30 days after
60%
44 / 73 earnings
Positive
+16.5%
Q3 2026
Best reaction
-21.7%
Q2 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.2% | -3.4% | +2.8% | |
| Q3 2026 | +16.5% | +13.8% | +11.8% | |
| Q2 2026 | +1.5% | +1.4% | -4.2% | |
| Q1 2026 | -5.8% | -6.4% | -2.3% | |
| Q4 2025 | +0.4% | -1.2% | +3.3% | |
| Q3 2025 | -1.2% | +0.6% | +6.1% | |
| Q2 2025 | +15.7% | +17.2% | +14.9% | |
| Q1 2025 | -10.9% | -10.3% | -17.9% | |
| Q4 2024 | +1.9% | +5.0% | +9.9% | |
| Q3 2024 | -2.5% | -2.4% | +4.1% | |
| Q2 2024 | -1.7% | +1.0% | +2.0% | |
| Q1 2024 | +7.4% | +4.2% | +1.8% | |
| Q4 2023 | +6.2% | +6.6% | +5.1% | |
| Q3 2023 | -3.2% | -5.4% | -8.7% | |
| Q2 2023 | +0.1% | +1.9% | -2.5% | |
| Q1 2023 | +0.8% | +3.7% | +8.6% | |
| Q4 2022 | +4.5% | +3.1% | -1.1% | |
| Q3 2022 | +4.1% | +5.2% | +9.7% | |
| Q2 2022 | +5.3% | +6.6% | +3.6% | |
| Q1 2022 | -3.3% | -4.6% | -0.1% | |
| Q4 2021 | +4.5% | +4.7% | +3.1% | |
| Q3 2021 | +1.0% | +1.9% | -4.1% | |
| Q2 2021 | +9.2% | +12.4% | +17.8% | |
| Q1 2021 | +4.6% | +1.2% | +4.1% | |
| Q4 2020 | +0.8% | +3.3% | +8.3% | |
| Q3 2020 | +5.7% | +8.6% | +0.8% | |
| Q2 2020 | -11.0% | -7.9% | -3.2% | |
| Q1 2020 | +4.0% | +1.5% | -3.0% | |
| Q4 2019 | +7.1% | +0.6% | +3.7% | |
| Q3 2019 | +1.9% | +5.4% | -0.4% | |
| Q2 2019 | -2.6% | +2.1% | -0.3% | |
| Q1 2019 | -7.1% | -5.8% | -2.8% | |
| Q4 2018 | -0.7% | -3.8% | +1.4% | |
| Q3 2018 | -5.7% | -9.7% | -11.2% | |
| Q2 2018 | -10.4% | -8.9% | -4.4% | |
| Q1 2018 | -2.3% | -3.1% | -11.3% | |
| Q4 2017 | +7.7% | +11.9% | +12.5% | |
| Q3 2017 | -6.6% | -7.6% | +1.7% | |
| Q2 2017 | -21.7% | -18.5% | -9.8% | |
| Q1 2017 | -1.4% | -2.1% | -6.9% | |
| Q4 2016 | +2.7% | — | — | |
| Q3 2016 | -6.4% | — | — | |
| Q2 2016 | -2.0% | — | — | |
| Q1 2016 | -4.1% | — | — | |
| Q4 2015 | +1.7% | — | — | |
| Q3 2015 | +5.7% | — | — | |
| Q2 2015 | -2.1% | — | — | |
| Q1 2015 | +2.2% | — | — | |
| Q4 2014 | +5.3% | — | — | |
| Q3 2014 | +0.7% | — | — | |
| Q2 2014 | +8.3% | — | — | |
| Q1 2014 | +5.4% | — | — | |
| Q4 2013 | +7.3% | — | — | |
| Q3 2013 | -2.3% | — | — | |
| Q2 2013 | +3.4% | — | — | |
| Q1 2013 | -1.0% | — | — | |
| Q4 2012 | -0.7% | — | — | |
| Q3 2012 | +3.0% | — | — | |
| Q2 2012 | +6.3% | — | — | |
| Q1 2012 | +0.7% | — | — | |
| Q4 2011 | -0.2% | — | — | |
| Q3 2011 | +2.3% | — | — | |
| Q2 2011 | +6.0% | — | — | |
| Q1 2011 | -0.7% | — | — | |
| Q4 2008 | +3.8% | — | — | |
| Q4 2010 | +3.8% | — | — | |
| Q3 2010 | -3.1% | — | — | |
| Q3 2009 | -3.1% | — | — | |
| Q2 2010 | -3.2% | — | — | |
| Q2 2009 | +8.9% | — | — | |
| Q1 2009 | +8.9% | — | — | |
| Q1 2010 | +8.9% | — | — | |
| Q4 2009 | +8.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro